Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives $14.00 Average Target Price from Analysts

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) has been given an average recommendation of “Hold” by the nine analysts that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and five have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $14.00.

Several equities analysts recently commented on the company. Citizens Jmp cut their target price on Bicycle Therapeutics from $12.00 to $8.00 and set a “market outperform” rating for the company in a research report on Wednesday, March 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Bicycle Therapeutics in a research report on Friday, April 10th. Citigroup restated a “market outperform” rating on shares of Bicycle Therapeutics in a research report on Wednesday, June 3rd. Morgan Stanley cut their price objective on Bicycle Therapeutics from $13.00 to $12.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 8th. Finally, Wall Street Zen downgraded Bicycle Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday, May 10th.

Bicycle Therapeutics Price Performance

Bicycle Therapeutics stock opened at $4.00 on Friday. The company has a market capitalization of $279.24 million, a PE ratio of -1.27 and a beta of 1.54. Bicycle Therapeutics has a one year low of $3.95 and a one year high of $9.18. The business has a 50 day simple moving average of $4.56 and a 200 day simple moving average of $5.47.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its earnings results on Thursday, April 30th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.25). The company had revenue of $0.89 million for the quarter, compared to the consensus estimate of $7.50 million. Bicycle Therapeutics had a negative return on equity of 35.74% and a negative net margin of 344.95%. Equities analysts anticipate that Bicycle Therapeutics will post -1.97 earnings per share for the current fiscal year.

Insider Transactions at Bicycle Therapeutics

In other Bicycle Therapeutics news, CEO Kevin Lee sold 5,967 shares of Bicycle Therapeutics stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $4.91, for a total value of $29,297.97. Following the completion of the transaction, the chief executive officer owned 613,029 shares in the company, valued at approximately $3,009,972.39. The trade was a 0.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 9,992 shares of company stock valued at $49,363. Insiders own 8.50% of the company’s stock.

Hedge Funds Weigh In On Bicycle Therapeutics

Several institutional investors have recently bought and sold shares of BCYC. Assetmark Inc. increased its stake in shares of Bicycle Therapeutics by 74.9% in the 3rd quarter. Assetmark Inc. now owns 3,625 shares of the company’s stock valued at $28,000 after buying an additional 1,552 shares during the period. Clearstead Advisors LLC increased its stake in shares of Bicycle Therapeutics by 234.2% in the 4th quarter. Clearstead Advisors LLC now owns 4,655 shares of the company’s stock valued at $33,000 after buying an additional 3,262 shares during the period. Royal Bank of Canada increased its stake in shares of Bicycle Therapeutics by 35.5% in the 1st quarter. Royal Bank of Canada now owns 14,470 shares of the company’s stock valued at $67,000 after buying an additional 3,788 shares during the period. Brooklyn Investment Group acquired a new stake in shares of Bicycle Therapeutics in the 4th quarter valued at $69,000. Finally, Ausdal Financial Partners Inc. acquired a new stake in shares of Bicycle Therapeutics in the 2nd quarter valued at $70,000. Institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.